Investor Relations
Overview
Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections. Our lead product candidate, lefamulin, is being developed as the first pleuromutilin antibiotic for intravenous (IV) and oral administration in humans. We reported positive topline efficacy and favorable tolerability results from the LEAP 1 and LEAP 2 pivotal Phase 3 trials for the treatment of community-acquired bacterial pneumonia (CABP) in adults. We believe lefamulin has the potential to be developed for additional uses and we are working to build a robust pipeline of products. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.
Events & Presentations
Upcoming
Prior
Wednesday January 23, 2019 8:30 AM EST
Nabriva Analyst & Investor Day
Tuesday November 27, 2018 11:00 AM EST
Piper Jaffray Healthcare Conference
Monday October 1, 2018 8:20 AM EDT
Nabriva Therapeutics at the Cantor Fitzgerald Global Healthcare Conference
SEC Filings
Investor Contacts
David Garrett
Vice President, Corporate Controller and Head of Investor Relations Nabriva Therapeutics plc
E-mail: david.garrett@nabriva.com